Zimmer Biomet Holdings ZBH underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 8 | 11 | 0 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 2 | 0 | 0 |
| 2M Ago | 1 | 0 | 7 | 0 | 0 |
| 3M Ago | 0 | 4 | 2 | 0 | 1 |
Analysts have recently evaluated Zimmer Biomet Holdings and provided 12-month price targets. The average target is $121.76, accompanied by a high estimate of $145.00 and a low estimate of $107.00. This current average has decreased by 4.31% from the previous average price target of $127.24.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Zimmer Biomet Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Raises | Outperform | $125.00 | $120.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $117.00 | $112.00 |
| Larry Biegelsen | Wells Fargo | Raises | Equal-Weight | $117.00 | $110.00 |
| Steven Lichtman | Oppenheimer | Lowers | Outperform | $135.00 | $145.00 |
| Jayson Bedford | Raymond James | Lowers | Outperform | $123.00 | $128.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $120.00 | $130.00 |
| Ryan Zimmerman | BTIG | Lowers | Buy | $126.00 | $134.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $110.00 | $113.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $120.00 | $125.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $112.00 | $117.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $115.00 | $120.00 |
| Joshua Jennings | TD Cowen | Lowers | Hold | $119.00 | $143.00 |
| Richard Newitter | Truist Securities | Maintains | Hold | $117.00 | $117.00 |
| Vijay Kumar | Evercore ISI Group | Maintains | In-Line | $113.00 | $113.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $120.00 | $130.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $130.00 | $140.00 |
| Jayson Bedford | Raymond James | Lowers | Outperform | $128.00 | $138.00 |
| Danielle Antalffy | UBS | Lowers | Sell | $107.00 | $112.00 |
| Steven Lichtman | Oppenheimer | Lowers | Outperform | $145.00 | $155.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $113.00 | $115.00 |
| Jeff Johnson | Baird | Lowers | Outperform | $145.00 | $155.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Zimmer Biomet Holdings's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Zimmer Biomet Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Zimmer Biomet Holdings analyst ratings.
Discovering Zimmer Biomet Holdings: A Closer Look
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Understanding the Numbers: Zimmer Biomet Holdings's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Zimmer Biomet Holdings showcased positive performance, achieving a revenue growth rate of 4.03% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Zimmer Biomet Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.15%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
